Condition: Advanced Solid Tumor · Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.
This description comes directly from the study's public registry record.
Medilink Study Team · +86 0512-62858368 · clinicaltrials@medilinkthera.com
Always discuss trial participation with your own doctor first.
| US-201 | New Haven, Connecticut, United States | Not Yet Recruiting |
| US-202 | Sarasota, Florida, United States | Recruiting |
| US-204 | Boston, Massachusetts, United States | Not Yet Recruiting |
| US-206 | Grand Rapids, Michigan, United States | Recruiting |
| US-205 | Nashville, Tennessee, United States | Recruiting |
| US-203 | Houston, Texas, United States | Not Yet Recruiting |
| US-207 | San Antonio, Texas, United States | Not Yet Recruiting |
| AUS-101 | Liverpool, New South Wales, Australia | Not Yet Recruiting |
| AUS-102 | Darlinghurst, Victoria, Australia | Recruiting |
| AUS-104 | Fitzroy, Victoria, Australia | Not Yet Recruiting |
| AUS-103 | Heidelberg, Victoria, Australia | Not Yet Recruiting |
| AUS-105 | Nedlands, Western Australia, Australia | Not Yet Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07197827